Contrast agent developer E-Z-EM has signed an agreement with pharmaceutical giant Eli Lilly for U.S. marketing of Lilly’s Glucagon for Injection product, a recombinant form of glucagon. Lilly will pay E-Z-EM a promotional fee based on sales of the
Contrast agent developer E-Z-EM has signed an agreement with pharmaceutical giant Eli Lilly for U.S. marketing of Lillys Glucagon for Injection product, a recombinant form of glucagon. Lilly will pay E-Z-EM a promotional fee based on sales of the injectable product, which is used in diagnostic procedures for the gastrointestinal system and for the treatment of severe hypoglycemia in diabetic patients. When used in gastrointestinal diagnostics, glucagon relaxes smooth muscles in the gastrointestinal tract, and may improve the quality of radiological images. The deal is part of E-Z-EMs strategy of forging healthcare alliances to bring key products to market, according to Howard Stern, chairman of the Wesbury, NY-based E-Z-EM. Lilly launched Glucagon in March.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.